Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.
Also in this 8-page issue: NCI closes its Tobacco Intervention Research Clinic, blaming flat budget, slow accrual.
Hope for FDA authority over tobacco products dies in Congress.
Patients urge Medicare to allow an open formulary for cancer treatment.
Promotions at MSKCC: Fuks heads radiation oncology, Pfister named chief of Head & Neck Medical Oncology Service.
Funding opportunities listed.
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Early-onset colorectal cancer is behaving like a new, biologically distinct disease, researchers note
One woman’s pregnancy shows how this distinction matters - Joe Fraumeni, founder of molecular epidemiology, dies at 93
“It’s hard to imagine a world without the presence of this gentle scientific giant.” - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data in ACS guideline support greater use of noninvasive tests to ease system strain, save lives - David Gius assumes role of director of the University of Cincinnati Cancer Center
